课题基金 / 基金详情

Dissecting the alphavirus entry receptor NRAMP

Dissecting the alphavirus entry receptor NRAMP
剖析甲病毒进入受体 NRAMP
批准号:
8296800
负责人:
Sara Cherry
金额:
$48.09万
依托单位:
依托单位国家:
美国
项目类别:
财政年份:
2012
资助国家:
美国
项目状态:
已结题
起止时间:
2012-07-01 至 2016-06-30

项目摘要

项目成果

Sara Cherry的其他基金

相似基金

相关文献

中文摘要
翻译
描述(由申请人提供):甲型病毒与细胞受体的相互作用可能在决定病毒趋向性和驱动病毒诱导的疾病方面发挥重要作用。然而,介导甲型病毒进入的病毒受体却知之甚少。利用Sindbis病毒进行的全基因组筛查发现,NRAMP是昆虫细胞中潜在的甲病毒进入受体。更多的研究表明,NRAMP也是委内瑞拉马脑炎病毒的进入受体。此外,在哺乳动物细胞中,普遍表达的同系物NRAMP2可以介导这些甲型病毒的感染。我们的长期目标是剖析NRAMPs在甲型病毒的传染性和致病机制中的作用,目的是开发对抗这些病原体的策略。我们将从病毒及其不同宿主的角度来研究这种重要的相互作用,包括确定其他甲型病毒是否使用NRAMP作为受体,以及确定介导NRAMP结合的病毒糖蛋白区域。由于哺乳动物有两个同源基因,NRAMP1和NRAMP2,我们还将测试NRAMP1和NRAMP2是否可以在功能上相互取代彼此作为甲病毒进入受体,并测试这两个分子中是否有一个或两个是甲病毒感染不同血统的原代细胞和体内所必需的。我们将利用我们开发的强大的分析方法来研究甲病毒在昆虫和哺乳动物细胞中的进入和感染,并将这些研究扩展到小鼠和成年苍蝇,以探索NRAMPs在病毒发病和传播中的作用。我们的中心假设是,解剖这些医学上重要的虫媒病毒与其受体的相互作用将揭示有助于开发针对这些尚未被研究的病原体的抗病毒治疗的机制,这些病原体目前还没有疫苗或疗法。 公共卫生相关性:甲型病毒是人类疾病的重要原因,了解甲型病毒受体如何调节病毒的趋向性和致病机制可能会导致针对这些人类病原体的新疗法的开发。这项建议中概述的研究将评估NRAMP1和NRAMP2作为甲型病毒进入昆虫和脊椎动物宿主的受体的作用,最终目的是阐明NRAMP/甲型病毒相互作用如何影响病毒致病。
英文摘要
DESCRIPTION (provided by applicant): Alphavirus interactions with cellular receptors are likely to play a major role determining viral tropism and driving virus-induced disease. However, the viral receptors that mediate alphavirus entry are poorly understood. A genome wide screen using Sindbis virus identified NRAMP as a potential alphavirus entry receptor in insect cells. Additional studies suggest that NRAMP is also an entry receptor for Venezuelan Equine Encephalitis virus. Furthermore, in mammalian cells the ubiquitously expressed homolog, NRAMP2, can mediate infection of these alphaviruses. Our long-term goal is to dissect the role of NRAMPs in infectivity and pathogenesis of alphaviruses with the goal of developing strategies to combat these pathogens. We will study this important interaction from both the perspective of the viruses and their varied hosts, including studies to determine whether additional alphaviruses use NRAMP as a receptor and to define the regions of the viral glycoproteins that mediate NRAMP binding. Since mammals have two homologous genes, NRAMP1 and NRAMP2, we will also test whether NRAMP1 and NRAMP2 can functionally substitute for one another as alphavirus entry receptors and test whether one or both of these molecules is required for alphavirus infection in primary cells from diverse lineages and in vivo. We will take advantage of powerful assays that we have developed to study alphavirus entry and infection both in insect and mammalian cells and extend these studies to mice and adult flies to explore the role of NRAMPs in viral pathogenesis and spread. Our central hypothesis is that dissecting the interactions of these medically important arboviruses with their receptor will reveal mechanisms that will aid in the development of antiviral treatments against these understudied pathogens for which there are no vaccines or therapeutics. PUBLIC HEALTH RELEVANCE: Alphaviruses are a significant cause of human disease and understanding how alphavirus receptors regulate viral tropism and pathogenesis is likely to result in the development of new therapies against these human pathogens. The studies outlined in this proposal will evaluate the role of NRAMP1 and NRAMP2 as entry receptors for alphaviruses in insects and vertebrate hosts, with the ultimate goal of elucidating how NRAMP/alphavirus interactions impact viral pathogenesis.
期刊论文(0)
专著(0)
科研奖励(0)
会议论文
Development and validation of antivirals against Flaviviruses
  • 批准号:
    10514328
  • 项目类别:
  • 资助金额:
    $489.76万
  • 财政年份:
    2022
  • 负责人:
    Sara Cherry
  • 依托单位:
Defining the role of microbiota-derived cyclic dinucleotides in priming antiviral immune defenses.
  • 批准号:
    10551893
  • 项目类别:
  • 资助金额:
    $40.63万
  • 财政年份:
    2020
  • 负责人:
    Sara Cherry
  • 依托单位:
Small Molecule Screening to Identify Novel Sars-CoV-2 Therapeutics
  • 批准号:
    10223018
  • 项目类别:
  • 资助金额:
    $33.6万
  • 财政年份:
    2020
  • 负责人:
    Sara Cherry
  • 依托单位:
Defining the role of microbiota-derived cyclic dinucleotides in priming antiviral immune defenses.
  • 批准号:
    10326823
  • 项目类别:
  • 资助金额:
    $40.63万
  • 财政年份:
    2020
  • 负责人:
    Sara Cherry
  • 依托单位:
海外基金